Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sandip Patel

Hematology & Oncology San Diego, CA Medical Doctor

NPI 1245481381 CMS profile 939763

200 W Arbor Dr, San Diego, CA 92103

Open in the dashboard

General payments

$294,795

242 records reported · program years 2019–2025

Research payments

$10,393

Paid to them · 7 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$11,304,777 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Sandip Patel of San Diego, CA is reported in the CMS Open Payments database as having received $294,795 across 242 general payments and $10,393 in research payments paid to them. Separately, studies naming them as principal investigator received $11,304,777 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

10 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $37,848 40
2024 General $47,990 40
2023 General $70,179 61
2023 Research $2,722 2
2022 General $41,002 22
2022 Research $3,200 1
2021 General $52,062 39
2021 Research $4,472 4
2020 General $19,466 15
2019 General $26,248 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sandip Patel
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Sandip Patel were reported at $37,848. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Sandip Patel Hematology & Oncology median Middle half National median
2019 $26,248 $529 $121–$2,516 $163
2020 $19,466 $339 $82–$2,213 $114
2021 $52,062 $263 $49–$1,965 $132
2022 $41,002 $416 $103–$2,395 $149
2023 $70,179 $542 $125–$2,646 $160
2024 $47,990 $692 $141–$3,008 $164
2025 $37,848 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $86,986 69 payments
  2. E.R. Squibb & Sons, L.L.C. $31,602 24 payments
  3. AstraZeneca UK Limited $18,782 14 payments
  4. Daiichi Sankyo Inc. $16,373 18 payments
  5. Amgen Inc. $15,528 13 payments
  6. Pfizer Inc. $15,509 14 payments
  7. Genentech USA, Inc. $11,997 14 payments
  8. Janssen Biotech, Inc. $11,525 9 payments
  9. Janssen Scientific Affairs, LLC $8,855 6 payments
  10. Merck Sharp & Dohme Corporation $8,800 3 payments
  11. Other $68,837 58 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $256,179 114 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $19,330 10 payments
  3. Honoraria $7,000 5 payments
  4. Food and Beverage $6,005 89 payments
  5. Travel and Lodging $3,092 14 payments
  6. Grant $1,957 1 payment
  7. Compensation for serving as faculty or as a speaker for a medical education program $1,154 2 payments
  8. Education $78 7 payments
Products named General payments · program years 2019–2025
  1. TAGRISSO $15,998 16 payments
  2. IMFINZI Oncology $14,752 14 payments
  3. IMFINZI Cardiovascular And Metabolism $9,723 1 payment
  4. ZEPZELCA $8,480 1 payment
  5. RYBREVANT $8,128 8 payments
  6. LORBRENA $5,707 8 payments
  7. TECENTRIQ $5,094 12 payments
  8. ENHERTU $4,945 2 payments
  9. Trodelvy $4,808 5 payments
  10. ELIQUIS $4,800 1 payment
  11. Other $61,771 73 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Pfizer Inc. $7,670 4 payments
  2. F. Hoffmann-La Roche AG $2,722 2 payments
  3. Eli Lilly and Company $2 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

396

Median for Hematology-Oncology: 604

Drug cost

$1,384,819

Median for Hematology-Oncology: $1,306,514

Branded share of claims

42.9%

Median for Hematology-Oncology: 31.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Tagrisso Osimertinib Mesylate Brand 53 $814,297
Lorbrena Lorlatinib Brand 19 $354,369
Alecensa Alectinib Hcl Brand 11 $191,510
Eliquis Apixaban Brand 40 $21,899
Ondansetron Odt Ondansetron Brand 25 $690
Dexamethasone Generic 59 $502
Levothyroxine Sodium Generic 29 $315
Omeprazole Generic 42 $284
Doxycycline Hyclate Generic 12 $209
Prochlorperazine Maleate Generic 18 $153

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$51,858

Medicare's payments for the services billed

Medicare patients

99

Average age 73

Services billed

738

49 women, 50 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Cancer 75%
High blood pressure 74%
Arthritis 44%
COPD 33%
Ischemic heart disease 31%
Depression 26%
Atrial fibrillation 23%
Diabetes 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
RYBREVANT
  • Janssen Biotech, Inc. $5,600
$5,600 — —
TAGRISSO
  • AstraZeneca Pharmaceuticals LP $4,936
$4,936 53 —
RETEVMO
  • Eli Lilly and Company $3,600
$3,600 — —
Trodelvy
  • Gilead Sciences, Inc. $1,520
$1,520 — —
ENHERTU
  • Daiichi Sankyo Inc. $215
$215 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

249 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record